Voyager Therapeutics, Inc.: operating income or loss
Operating income or loss for Voyager Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Voyager Therapeutics, Inc. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -131,844,000 | USD | 2026-03-09 | 10-K · 0001104659-26-025197 |
| 2024-01-01 | 2024-12-31 | -83,287,000 | USD | 2026-03-09 | 10-K · 0001104659-26-025197 |
| 2023-01-01 | 2023-12-31 | 122,014,000 | USD | 2026-03-09 | 10-K · 0001104659-26-025197 |
| 2022-01-01 | 2022-12-31 | -50,837,000 | USD | 2025-03-11 | 10-K · 0001558370-25-002703 |
| 2021-01-01 | 2021-12-31 | -73,618,000 | USD | 2024-02-28 | 10-K · 0001558370-24-001988 |
| 2020-01-01 | 2020-12-31 | 27,384,000 | USD | 2023-03-07 | 10-K · 0001558370-23-002989 |
| 2019-01-01 | 2019-12-31 | -51,679,000 | USD | 2022-03-08 | 10-K · 0001558370-22-003015 |
| 2018-01-01 | 2018-12-31 | -91,095,000 | USD | 2021-02-25 | 10-K · 0001558370-21-001865 |
| 2017-01-01 | 2017-12-31 | -71,863,000 | USD | 2020-03-03 | 10-K · 0001558370-20-001974 |
| 2016-01-01 | 2016-12-31 | -41,299,000 | USD | 2019-02-26 | 10-K · 0001558370-19-001105 |
| 2015-01-01 | 2015-12-31 | -20,254,000 | USD | 2018-03-14 | 10-K · 0001558370-18-002038 |
| 2014-01-01 | 2014-12-31 | -14,367,000 | USD | 2017-03-15 | 10-K · 0001558370-17-001797 |
Related financial histories
- Voyager Therapeutics, Inc.: total assets
- Voyager Therapeutics, Inc.: total liabilities
- Voyager Therapeutics, Inc.: stockholders equity
- Voyager Therapeutics, Inc.: cash and cash equivalents
- Voyager Therapeutics, Inc.: net income or loss
- Voyager Therapeutics, Inc.: operating cash flow
- Voyager Therapeutics, Inc.: capital expenditure payments
- Voyager Therapeutics, Inc.: revenue
- Voyager Therapeutics, Inc.: contract revenue excluding tax
- Voyager Therapeutics, Inc.: financing cash flow
- Voyager Therapeutics, Inc.: investing cash flow
- Voyager Therapeutics, Inc.: retained earnings or deficit
- Voyager Therapeutics, Inc.: basic weighted-average shares
- Voyager Therapeutics, Inc.: diluted weighted-average shares
- Voyager Therapeutics, Inc.: basic earnings per share
- Voyager Therapeutics, Inc.: diluted earnings per share
- Voyager Therapeutics, Inc.: income tax expense or benefit
- Voyager Therapeutics, Inc.: net property, plant and equipment
- Voyager Therapeutics, Inc.: share-based compensation expense
- Voyager Therapeutics, Inc.: current assets
- Voyager Therapeutics, Inc.: current liabilities
- Voyager Therapeutics, Inc.: current accounts payable
- Voyager Therapeutics, Inc.: operating expenses
- Voyager Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Voyager Therapeutics, Inc. / CIK 0001640266
- Captured
- 2026-09-21T17:21:36.313Z
- SEC response SHA-256
8090dbaa25dde9bd5981886fdac01f04bbe6c04ceaca1eba74d87843f38b004e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001640266.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))